Fig 1.
Immunohistochemical analysis of total FAK and pFAK-Y397 expression in osteosarcoma tissues.
(A, B) Negative expression, (C, D) weak expression, (E, F) moderate expression, (G, H) strong expression. (I, J) Strongly diffused total FAK (I-right) or pFAK-Y397 (J-right) expression in osteosarcoma, in contrast to diminished total FAK (I-left) or pFAK-Y397 (J-left) expression in adjacent epiphyseal growth plates. Original magnifications, x400 (A-H), x100 (I, J). Analysis of immunohistochemistry of total FAK and pFAK-Y397. (K) Percentage of positive tumor cells classified into 4 categories: 0, no staining; 1, < 25%; 2, 25–49%; 3, 50–74%; 4, 75–100%. (L) Staining intensity of positive tumor cells: 0, none; 1, weak; 2, moderate; 3, strong. (M) Overall score for total FAK or pFAK-Y397 expression in patients with osteosarcoma. The scores from staining percentage and intensity were added to yield the overall scores of 0, negative; 1–2, weak; 3–4, moderate; 5–7, overexpression.
Table 1.
Relationships between clinicopathologic characteristics and total FAK, pFAK-Y397 expression in primary osteosarcoma tissues of all patients with osteosarcoma, and patients with osteosarcoma presented with metastases at diagnosis or developed metastases during treatment/follow-up.
(non-overexpression = negative or weak or moderate expression)
Table 2.
Kaplan-Meier survival analyses for overall survival of all patients with osteosarcoma and for overall survival and post metastases overall survival of patients with osteosarcoma presented with metastases at diagnosis or developed metastases during treatment/follow-up.
Fig 2.
Kaplan-Meier survival curves of overall survival for patients with metastatic osteosarcoma.
(A) Presence of metastasis at diagnosis or during treatment/follow-up (survival rates, 5.3% vs 21.4%, P = 0.037). (B) Time to metastases; at diagnosis, ≤ 12 months, > 12 months (5.3% vs 0% vs 37.5%, P = 0.028). (C) pFAK-Y397 overexpression and non-overexpression (4.8% vs 25%, P = 0.044). (D) Post metastases overall survival (PMOS) of patients with metastatic osteosarcoma stratified by pFAK-Y397 overexpression and non-overexpression (4.8% vs 25%, P = 0.029).
Table 3.
Multivariate Cox regression analyses for overall survival of all patients with osteosarcoma, and for overall survival and post metastases overall survival of patients with osteosarcoma presented with metastases at diagnosis or developed metastases during treatment/follow-up.